Skip to main content

Kisoji Biotechnology

  • | Biotech or pharma, therapeutic R&D

KisoJi has created the world’s largest single-domain antibody database—over 25 million validated antibodies—to power its proprietary AI platform. 

This unmatched dataset enables KisoJi to pioneer transformative therapeutic breakthroughs using its antibody platform, which includes:

  • KisoMouse: A multi-species camelid transgenic mouse generating highly drug-like biological antibodies across all target epitopes.
  • KisoSeek: AI tools for paratope mapping and structural antibody search, enabling real-time, precise analysis of antibody repertoires.
  • KisoBody: A cutting-edge platform for generating multispecific antibodies with unprecedented yield and multiple mechanisms of action.

Through its platform, KisoJi has discovered its lead program, KJ-103, a first in class naked TROP2 antibody that will enter the clinic in 2026.


KisoJi is currently raising a financing round to scale its AI platform and expand its pipeline of innovative antibody medicines addressing the world’s most devastating diseases.

Address

Montreal
Que
Canada

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors